Five years after acquiring Inlog from US-based industrial group Haemonetics, Abenex announces the trade sale of the medical software provider specialised in blood product traceability and laboratory management. This transaction marks the conclusion of a strategic and operational partnership that enabled Inlog to reach a new stage of development, both in France and internationally.

 

A key player in the transmission and medical data protection

Founded in 1992 in Limonest (Rhône), Inlog has since become one of Europe’s leading medical software providers, specialising in solutions for laboratories, hospitals, and blood transfusion centres. Its software suites are used by over 630 public and private clients across 12 countries, including major public player of the blood transfusion and several Red Cross institutions internationally. Inlog also offers best-in-class solutions for quality management and regulatory compliance within laboratories. The Group employs around 80 people worldwide.

 

Accelerated growth driven by a focused strategy

Since Abenex’s investment in 2020, Inlog has undergone an ambitious transformation phase, establishing itself as an independent company following its carve-out from the Haemonetics Group and accelerating its growth trajectory. The management team has been strengthened, a new ERP system implemented, and R&D activities brought in-house to ensure tighter control over innovation. Geographically, Inlog expanded its presence in the DACH region with the opening of a subsidiary in Germany in 2022, to better serve the German, Swiss, and Austrian markets. In parallel, the company completed three strategic acquisitions: Moonchase in Belgium (2023), which enhanced its offering for laboratories with a web-based solution and entering the Benelux region; and Ubilab (2023) and Viskali (2022) in France, which deepened Inlog’s expertise in quality management software. Inlog has achieved significant growth, doubled its sales and solidified its position as a leading provider of critical processes digitalisation services in the healthcare sector.

 

A new chapter to accelerate innovation and international expansion

This change in ownership marks the beginning of a new phase of development for Inlog, with a clear ambition to strengthen its international footprint and drive innovation in response to the evolving digital and regulatory challenges of the healthcare sector. This new chapter builds on the solid foundations established in recent years: sustained growth momentum, a recognised software offering, and a resilient business model. It also extends the company’s societal commitments — Inlog became a purpose-driven company in 2023, with a governance framework aligned with long-term sustainability and positive impact objectives.

 

David Kalfon, CEO and President of Inlog, comments:
“We are extremely proud of the journey we have taken alongside Abenex. Their support has been instrumental in structuring our growth, expanding and modernising our software suite, and entering new markets. We look forward to this next chapter with confidence and enthusiasm, alongside our new shareholder.”

 

Thomas Peretti, Partner at Abenex, adds:
“Inlog is a prime example of our engaged and operational investment approach, working alongside passionate management teams. In just five years, the company has undergone a profound transformation — expanding its geographic footprint, significantly improving its ESG performance, and broadening its software offering, all while maintaining an outstanding level of quality and customer satisfaction. This remarkable trajectory also translated into a strong performance for our Funds. We are proud to have played a role in this success and confident in Inlog’s ability to continue its development.”

 

Deal participants (Sell-side)

Sellers

• Inlog: David Kalfon and the management team
• Abenex: Christian Dorléac, Thomas Peretti, Angèle France, Foucault Crombez

Sell-Side Advisors

• M&A: Lincoln International (Matthieu Rosset, François Rispoli, François-Xavier Moisan, Arthur Legrand, Adrien Senechal, Jérémy Eyer) and Atguen Advisory (Jean-David Sultan)
• M&A Legal: McDermott Will & Schulte (Grégoire Andrieux, Robin Lamour, Charlotte Michellet)
• Management Advisory: Duroc Partners (Erwan Bordet, Faustine Paoluzzo)
• Financial DD: 8Advisory (Gennat Mouline, Frédéric Blache, Xavier Parenty, Alexandre Pommier)
• Commercial and Strategic DD: EY-Parthenon (Gianluigi Indino, Arnaud Laferte, Divya Claver, Hugo Jennequin)
• Legal and Social DD: Grant Thornton (Caroline Luche Rocchia, Christine D’Ovidio, Sahra Hagani, Natalia Moya-Fernandez)
• Tax DD: Arsène Taxand (David Chaumontet, Magali Mazzuco)
• IT DD: Vaultinum (Philippe Thomas, Juliette Cazenave, Jonathan Berdah)
• ESG DD: PwC (Jorik Geiger)